Annual Report 2022

CHAIRMAN’S STATEMENT 7 The United Laboratories International Holdings Limited Annual Report 2022 REVIEW OF 2022 During the year, we overcome the impact of the COVID-19 pandemic and achieved satisfactory operating results thanks to our active efforts to promote R&D, production and supply, and sales services. On behalf of the board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company” or “The United Laboratories”), I am pleased to present to our shareholders and partners the annual results of the Company and its subsidiaries (the “Group”) for the year ended 31 December 2022 (the “Year”). In 2022, the Group recorded revenue of approximately RMB11,334.3 million, representing an increase of approximately 16.8% year-on-year. Profit attributable to owners of the Company was RMB1,581.1 million, representing a year-on-year increase of 60.0%. Earnings per share were RMB86.89 cents. The Board recommends the payment of a final dividend of RMB14 cents per share and a special dividend of RMB6 cents per share for the year ended 31 December 2022. Accelerating R&D and innovation In 2022, the Group’s investment in R&D amounted to RMB593.6 million, representing a year-on-year increase of 27.6%. Significant progress was made in R&D of drugs for diabetes, ophthalmology and other diseases. In response to the requirement of accelerating the development of biomedicine under the “14th Five-Year Plan” and the Long-Range Objectives through the Year 2035 of China, the Group established The United Bio-Technology (Hengqin) Co., Ltd. and settled in Traditional Chinese Medicine Science and Technology Industrial Park of Cooperation between Guangdong and Macao （粵澳合作中醫藥科技產業園） . Relying on the professional platform resources, we will accelerate the R&D of high-end biological drugs for chronic diseases, enrich our pipeline with new drugs for energy metabolism, inflammation and autoimmune diseases, and strengthen international cooperation and project introduction. Through its increasingly mature R&D platform for innovative chemical drugs, the Group has initiated R&D of numerous new drugs such as those for autoimmune diseases and ophthalmology as well as high-end anti-infective drugs, and actively expanded the exchange and cooperation with leading domestic and foreign R&D platforms. As innovation is the fundamental driving force for our development, we will efficiently promote the research, development and marketing of new drugs, expand the fields of drug research, foster greater global outlook, and improve the high-end talent team in order to continuously enhance our competitiveness and creativity.